Usefulness of DORNASE (Pulmozyme®) in Patients With COVID-19 Respiratory Insufficiency on High-Flow Oxygen Therapy
Overview
- Phase
- Phase 4
- Intervention
- Saline
- Conditions
- COVID-19 Pneumonia
- Sponsor
- University Medical Centre Ljubljana
- Enrollment
- 10
- Locations
- 1
- Primary Endpoint
- Intubations
- Status
- Terminated
- Last Updated
- 3 years ago
Overview
Brief Summary
COVID-19 pneumonia manifests among others with a thick bronhial secretion. It contains an increased number of neutrophil extracellular traps (NETs), formed during netosis. DNA is a major component in NETs. DNAse alfa (Pulmozyme®, Roche) is a recombinant human enzyme, registered for inhalations in patients with Cystic fibrosis, in which NETs are also a typical characteristic. DNAse alfa inhalations are typically well tolerated and with no major side effects. Some initial reports exist of using DNAse alfa inhalations in COVID-19 patients, that had benefitial effects. There are some trials registered with ClinicalTrials, investigating the usufulness of DNAse alfa in intubated patients, but the investigators have no knowledge of a trial, investigating the usufulness of this drug in patients receiving High Flow Nasal Oxygen therapy.
Investigators
Marko Zlicar
Head of department
University Medical Centre Ljubljana
Eligibility Criteria
Inclusion Criteria
- •Positive SARS-CoV-2 RNA PCR swab
- •inflamatory phase of infection
Exclusion Criteria
- •pregnancy
- •previous treatment with DNAse alfa
Arms & Interventions
4% saline
4% Saline inhalations twice daily
Intervention: Saline
Pulmosyme
DNAse alpha inhalations twice daily
Intervention: Dornase Alfa
Outcomes
Primary Outcomes
Intubations
Time Frame: 7 days
Number of intubations necessary
Secondary Outcomes
- PaO2/FiO2(7 days)
- inflamation(7 days)